According to a Moderna study, following a first dose of it’s vaccine, protection against the coronavirus had a 93% effectiveness, compared to a 100% effectiveness fourteen days after a second dose.
The study involved approximately 3,700 adolescent participants. Two-thirds received the vaccine, and one-third received a placebo. Participants who had received the vaccine showed no signs of COVID, while among those who had been given a placebo, were four cases of illness.
The common adverse side-effects reported by those vaccinated are the usual complaints of pain at injection site, fatigue, headache, and muscle soreness. These side-effects were a common complaint after each of the injections during the Phase 2/3 clinical study.
As of now, Moderna’s vaccine is available only to adults eighteen years of age and over, as it’s initial testing was done in adults. They hope to be able to use their vaccine in children as young as twelve after authorization from the FDA.
“We will submit these results to the U.S. FDA and regulators globally in June and request authorization,” says Stephane Bancel, CEO of Moderna.
Sources: The Week, USA Today.